Beyond efficacy parity: a novel cost-equilibrium framework for value assessment of competing third-line therapies in metastatic colorectal cancer.

Front Pharmacol · 2025 · PMC12390821 · PMID 40894226

Europe PMC DOI

hedged sentence

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

did not reach statistical significancep = 0.078so close (0.05 < p ≤ 0.1)

A trending difference in primary tumor location was noted, with the regorafenib group showing right-sided colon predominance (60%) versus rectal predominance (55%) in the fruquintinib group, though this did not reach statistical significance (p = 0.078).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.